Evidence map›Paper›PMID 28222734›Full record

ArticleWorld journal of surgical oncology2017

Diabetes and beta-adrenergic blockage are risk factors for metastatic prostate cancer.

Malte Krönig, Christian Haverkamp, Antonia Schulte, Laura Heinicke, Kathrin Schaal, Vanessa Drendel, Martin Werner, Ulrich Wetterauer, Wolfgang Schultze-Seemann, Cordula Annette Jilg

Abstract read
In one paragraph

Article in World journal of surgical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Malte KrönigDepartment of Urology, Uniklinikum Freiburg, Hugstetter Strasse 55, 79106, Freiburg, Germany. malte.kroenig@uniklinik-freiburg.de.ORCID http://orcid.org/0000-0003-0787-992X
Christian HaverkampIT-Department, Uniklinikum Freiburg, Agnesenstrasse 6-8, 79106, Freiburg, Germany.
Antonia SchulteDepartment of Urology, Uniklinikum Freiburg, Hugstetter Strasse 55, 79106, Freiburg, Germany.
Laura HeinickeDepartment of Urology, Uniklinikum Freiburg, Hugstetter Strasse 55, 79106, Freiburg, Germany.
Kathrin SchaalDepartment of Urology, Uniklinikum Freiburg, Hugstetter Strasse 55, 79106, Freiburg, Germany.
Vanessa DrendelInstitut of Clinical Pathology, Uniklinikum Freiburg, Breisacher Strasse 115a, 79106, Freiburg, Germany.
Martin WernerInstitut of Clinical Pathology, Uniklinikum Freiburg, Breisacher Strasse 115a, 79106, Freiburg, Germany.
Ulrich WetterauerDepartment of Urology, Uniklinikum Freiburg, Hugstetter Strasse 55, 79106, Freiburg, Germany.
Wolfgang Schultze-SeemannDepartment of Urology, Uniklinikum Freiburg, Hugstetter Strasse 55, 79106, Freiburg, Germany.
Cordula Annette JilgDepartment of Urology, Uniklinikum Freiburg, Hugstetter Strasse 55, 79106, Freiburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe evaluated the influence of comorbidity inferred risks for lymph node metastasis (pN1) and positive surgical margins (R1) after radical prostatectomy in order to optimize pretherapeutic risk classification. We analyzed 454 patients after radical prostatectomy (RP) between 2009 and 2014. Comorbidities were defined by patients' medication from our electronic patient chart and stratified according to the ATC WHO code. Endpoints were lymph node metastasis (pN1) and positive surgical margins (R1).

resultsRates for pN1 and R1 were 21.4% (97/454) and 29.3% (133/454), respectively. In addition to CAPRA and Gleason score, we identified diabetes as a significant medication inferred risk factor for pN1 (OR 2.9, p = 0.004/OR 3.2, p = 0.001/OR 3.5, p = 0.001) and beta-blockers for R1 (OR 1.9, p = 0.020/OR 2.9, p = 0.004). Patients with diabetes showed no statistically significant difference in Gleason score, CAPRA Score, PSA, and age compared to non-diabetic patients.

conclusionsWe identified diabetes and beta1 adrenergic blockage as significant risk factors for lymph node metastasis and positive surgical margins in prostate cancer (PCa). Patients at risk will need intensive pretherapeutic staging for optimal therapeutic stratification.

Indexed as

Adrenergic beta-AntagonistsAgedCombined Modality TherapyDiabetes MellitusFollow-Up StudiesHumansLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm StagingPrognosisProstatectomyProstatic NeoplasmsAdrenergic beta-AntagonistsBeta-adrenergic blockageDiabetesMetastasisProstate cancer

Identifiers

PMID28222734
PMCPMC5320736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.